Evidence map›Paper›PMID 32387455›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2020

Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas.

S Derks, L K de Klerk, X Xu, T Fleitas, K X Liu, Y Liu, F Dietlein, C Margolis, A M Chiaravalli, A C Da Silva and 10 more

Open access · greenAbstract read
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 2 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 2 syntheses or guidelines pooled it, 150 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Humoral immunity in cancer.Signal transduction and targeted therapy · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. CD8Cancer science · 2026
    Article
  11. Article
  12. Spatially defined danger zone shapes gastric cancer progression through CCDC80Apoptosis : an international journal on programmed cell death · 2026
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 4 countries.

S DerksDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands. Electronic address: s.derks@amsterdamumc.nl.
L K de KlerkDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Dana-Farber Cancer Institute, Boston, USA.
X XuDepartment of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
T FleitasBiomedical Research Institute INCLIVA, CIBERONC, University of Valencia, Valencia, Spain.
K X LiuDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, USA.
Y LiuBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, USA.
F DietleinDana-Farber Cancer Institute, Boston, USA; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, USA.
C MargolisDana-Farber Cancer Institute, Boston, USA; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, USA.
A M ChiaravalliDepartment of Pathology, Ospedale di Circolo, Varese, Italy.
A C Da SilvaDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.
S OginoDana-Farber Cancer Institute, Boston, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, USA.
F G AkarcaDana-Farber Cancer Institute, Boston, USA.
G J FreemanDana-Farber Cancer Institute, Boston, USA.
S J RodigDepartment of Pathology and Center for Immuno-Oncology.
J L HornickDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.
E van AllenDana-Farber Cancer Institute, Boston, USA; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, USA.
B LiDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, USA.
S X LiuDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, USA.
V ThorssonInstitute for Systems Biology, Seattle, USA.
A J BassDana-Farber Cancer Institute, Boston, USA; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, USA. Electronic address: adam_bass@dfci.harvard.edu.
Broad Institute · USDana-Farber Cancer Institute · USBrigham and Women's Hospital · USOncode Institute · NLHarvard University · USInstitute for Systems Biology · USShanghai Jiao Tong University · CNUniversitat de València · ES

Funding

Transformed Esophageal Epithelial Cells and the Tumor MicroenvironmentP01CA098101 · NCI · UNIVERSITY OF PENNSYLVANIA · PI NAKAGAWA, HIROSHI · 2003 to 2023
$31.7M
Accelerating Transdisciplinary Epidemiology of Colorectal CancerR35CA197735 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2015 to 2021
$6.0M
NCI NIH HHS P01 CA098101NCI NIH HHS R35 CA197735
6 · The paper itself

Abstract

backgroundGastroesophageal adenocarcinomas (GEAs) are heterogeneous cancers where immune checkpoint inhibitors have robust efficacy in heavily inflamed microsatellite instability (MSI) or Epstein-Barr virus (EBV)-positive subtypes. Immune checkpoint inhibitor responses are markedly lower in diffuse/genome stable (GS) and chromosomal instable (CIN) GEAs. In contrast to EBV and MSI subtypes, the tumor microenvironment of CIN and GS GEAs have not been fully characterized to date, which limits our ability to improve immunotherapeutic strategies. PATIENTS AND

methodsHere we aimed to identify tumor-immune cell association across GEA subclasses using data from The Cancer Genome Atlas (N = 453 GEAs) and archival GEA resection specimen (N = 71). The Cancer Genome Atlas RNAseq data were used for computational inferences of immune cell subsets, which were correlated to tumor characteristics within and between subtypes. Archival tissues were used for more spatial immune characterization spanning immunohistochemistry and mRNA expression analyses.

resultsOur results confirmed substantial heterogeneity in the tumor microenvironment between distinct subtypes. While MSI-high and EBV+ GEAs harbored most intense T cell infiltrates, the GS group showed enrichment of CD4+ T cells, macrophages and B cells and, in ∼50% of cases, evidence for tertiary lymphoid structures. In contrast, CIN cancers possessed CD8+ T cells predominantly at the invasive margin while tumor-associated macrophages showed tumor infiltrating capacity. Relatively T cell-rich 'hot' CIN GEAs were often from Western patients, while immunological 'cold' CIN GEAs showed enrichment of MYC and cell cycle pathways, including amplification of CCNE1.

conclusionsThese results reveal the diversity of immune phenotypes of GEA. Half of GS gastric cancers have tertiary lymphoid structures and are therefore promising candidates for immunotherapy. The majority of CIN GEAs, however, exhibit T cell exclusion and infiltrating macrophages. Associations of immune-poor CIN GEAs with MYC activity and CCNE1 amplification may enable new studies to determine precise mechanisms of immune evasion, ultimately inspiring new therapeutic modalities.

Indexed as

AdenocarcinomaStomach NeoplasmsHumansImmunohistochemistryMicrosatellite InstabilityTumor Microenvironmentchromosomal instabilitygastric cancer subtypesimmunotherapytertiary lymphoid structure (TLS)

Identifiers

PMID32387455
PMCPMC7690253
OpenAlexW3021600405

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.